Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Combined With Aspirin in High-risk HCC
NCT02748304Terminated
- Sponsor
- Fudan University
- Start
- Apr 2016
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of sorafenib and aspirin in hepatocellular carcinoma (HCC) (3 arms), sponsored by Fudan University. Primary endpoint: Overall Survival at 5 years. Started Apr 2016; status: terminated.
02
Drugs
sorafenibaspirin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02748304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748304.